Kusum Sharma,Kaitlin E Sundling,Ranran Zhang et al.
Kusum Sharma et al.
In USA, colorectal cancer is the third most commonly diagnosed cancer in men, second in women, as well as the third leading cause of cancer deaths (Siegel et al. in Cancer J Clin 73:1-112, 2023 [109]). Worldwide, colorectal cancer is the se...
Muhamad Serhal,Ahsun Riaz,Riad Salem et al.
Muhamad Serhal et al.
Management of hepatic malignancies is a multidisciplinary task with the involvement of hepatologists, medical/surgical/radiation oncologists, transplant surgeons, and interventional radiologists. Patients should be selected for a specific t...
Emanuel Eguia,Talia Baker,Marshall Baker
Emanuel Eguia
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the eighth most common cancer in women worldwide. It is also the second leading cause of cancer death worldwide, with 780,000 deaths in 2018. Seventy-two percent of H...
Cholangiocarcinoma [0.03%]
胆管癌
Matthew E Dixon,Michael Williams,Sam G Pappas
Matthew E Dixon
Cholangiocarcinoma (CC) is a heterogeneous group of malignancies that originates at any point along the biliary tree. CC is an uncommon malignancy as it represents approximately 3% of all gastrointestinal malignancies, though its global inc...
Gallbladder Cancer [0.03%]
胆囊癌
Clayton T Marcinak,Daniel E Abbott
Clayton T Marcinak
Gallbladder carcinoma (GBC) is the most common biliary epithelial malignancy, with an estimated incidence of 1.13 cases per 100,000 in the United States (Hundal and Shaffer in Clin Epidemiol 6:99-109, 2014 1; Henley et al. in Cancer Epidemi...
A NSQIP-Based Randomized Clinical Trial Evaluating Choice of Prophylactic Antibiotics for Pancreaticoduodenectomy [0.03%]
基于NSQIP的随机临床试验评估胰十二指肠切除术预防性抗生素的选择
Brian C Brajcich,Clifford Y Ko,Jason B Liu et al.
Brian C Brajcich et al.
Surgical site infection is a common complication following pancreaticoduodenectomy and is a major source of postoperative morbidity. Surgical site infection is more common among patients who undergo preoperative biliary instrumentation, lik...
Randomized Controlled Trial
Cancer treatment and research. 2024:192:131-145. DOI:10.1007/978-3-031-61238-1_7 2024
Gastrointestinal Malignancies: Pancreatic Cancer Clinical Trials in Neoadjuvant Chemotherapy [0.03%]
胃肠恶性肿瘤：新辅助化疗胰腺癌临床试验
Paola Barrios,Akhil Chawla
Paola Barrios
Surgical resection is the only known treatment associated with long-term survival in pancreatic adenocarcinoma. While adjuvant therapy has shown a clear survival benefit, neoadjuvant chemotherapy has gained interest due to its ability to pr...
Tarek Abi-Saab,Ashley M Cunningham,Patrick S Rush et al.
Tarek Abi-Saab et al.
This chapter explores the pathologic features of benign and malignant lesions of the pancreas. As pathologic classifications evolve particularly for cystic lesions and neuroendocrine tumors, it is important for physicians who treat patients...
Dominic Vitello,Mark S Talamonti
Dominic Vitello
Pancreatic ductal adenocarcinoma (PDAC) continues to be a daunting clinical challenge. In 2023, it is estimated that 64,000 people will be newly diagnosed with PDAC and 51,000 people will die from PDAC. By 2030, PDAC is predicted to be the ...
Mark Sharobim,Eduard Matkovic,Michael Schwalbe et al.
Mark Sharobim et al.
Neuroendocrine neoplasms are a heterogeneous group of tumors that can occur in almost any organ and share a common neuroendocrine phenotype. © 2024. The...